Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

NCT01427244 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT01427244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01427244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Withdrawn
Start date
August 31, 2011
Completion date
September 30, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paget's disease of the vulva